To investigate anti‐SIRPα mAb therapy inhibitory effects on sporadic solid neoplastic tumor growth, we used a conditional APC knockout CPC‐APC mouse model, in which colon‐preferential gene targeted mice recapitulate human colorectal cancer.16 We assessed anti‐SIRPα mAb treatment effects on tumor growth in the colon and small intestine of B6 background‐CPC‐APC mice that received anti‐SIRPα mAb weekly from 8 weeks of age until death. This evidence concerns the gene SIRPA and colorectal cancer.